RELIGARE ENTERPRISES LTD.

Religare Enterprises Limited has received approval from the Reserve Bank of India (RBI) for the appointment of four individuals as Additional Directors to its Board. These appointments, effective November 3, 2026, are for a term not exceeding five years. The approved directors are Dr. Anand Chand Burman, Mr. Aditya Chand Burman, Mr. Mohit Burman, and Mr. Jimeet Vipul Modi. They will serve as Non-Executive and Non-Independent Directors. All four individuals are confirmed not to be debarred from holding directorships by any regulatory authority. This development follows an earlier announcement on November 13, 2025, regarding these proposed appointments.

Religare Enterprises Limited (REL) announced that its material subsidiary, Care Health Insurance Limited (CHIL), has successfully allotted 15,000 unsecured, subordinated, listed, taxable, redeemable, non-convertible debentures aggregating to ₹150 Crore. These debentures carry a coupon rate of 10.50% per annum and have a tenure of 10 years, with a maturity date of October 30, 2036. The issuance is on a private placement basis and will be listed on the National Stock Exchange of India Limited. The allotment is subject to IRDAI laws, particularly concerning solvency margins and net loss, which may affect interest payments.

Religare Finvest Limited (RFL), a material subsidiary of Religare Enterprises Limited, has appointed Mr. Gaurav Sharma as its Chief Technology Officer (CTO) effective October 06, 2026. Mr. Sharma brings nearly 30 years of experience in financial services and technology, with a strong background in digital transformation, enterprise technology modernization, analytics, and AI. Previously, he served as CTO at IIFL Finance Group and Group CTO at Poonawalla Fincorp, where he led significant technology initiatives and transformations. His expertise is expected to bolster RFL's technological capabilities.

Religare Enterprises Ltd has announced the closure of its trading window for dealing in the company's shares. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from October 01, 2026, and will reopen 48 hours after the declaration of the Un-Audited Financial Results for the quarter ended September 30, 2026. The specific date for the Board of Directors' meeting to consider and approve these financial results will be communicated separately.

Religare Enterprises Ltd announced that its members, at the 42nd Annual General Meeting held on September 24, 2026, approved the re-designation of Mr. Arjun Lamba as the Managing Director. This re-designation is effective from August 12, 2026, for the remainder of his tenure, with no changes to his existing terms and conditions. The company confirmed that Mr. Lamba is not debarred from holding the office of director by any SEBI order or other authority.

Religare Enterprises Limited conducted its 42nd Annual General Meeting (AGM) on September 24, 2026, via video conferencing (VC/OAVM). The meeting was held in compliance with MCA and SEBI circulars, as well as the Companies Act, 2013, and SEBI Listing Regulations. The proceedings were conducted in accordance with Secretarial Standard on General Meetings (SS-II). Ms. Tanvi Gambhir, Company Secretary of a step-down subsidiary, assisted in conducting the meeting due to a vacancy in the Company Secretary position at Religare Enterprises. The Chairman, Mr. Rajender Mohan Malla, introduced the directors and key management personnel present, including the Managing Director, CFO, and Group General Counsel. The Scrutinizer, Secretarial Auditors, and Statutory Auditors were also present. Voting results and the scrutinizer's report will be submitted in due course.

Religare Enterprises Ltd has announced the establishment of its new corporate office located at Office No. 401, 4th floor, Arena Space, Plot no. 20, Jogeshwari Vikhroli, Link Road, Shyam Nagar, Jogeshwari East, Mumbai. The new office will be operational starting September 18, 2026. This move is in compliance with SEBI Listing Regulations.

Religare Enterprises Limited's material subsidiary, Care Health Insurance Limited (CHIL), has successfully allotted 10,000 unsecured, subordinated debentures worth ₹100 Crore. These debentures carry a fixed coupon rate of 10.00% per annum and will be listed on the National Stock Exchange of India Limited's Debt Segment. The issuance is in the nature of subordinated debt, in compliance with IRDAI and SEBI regulations. The debentures have a tenure of 10 years, with a maturity date of September 18, 2036, subject to potential call options after 5 years. Interest payments are annual, but subject to regulatory approvals and the company's financial health, with no cumulative interest payment.

Religare Enterprises Ltd announced the continuation of Mr. Rajender Mohan Malla as the Non-Executive Chairperson for the fourth quarter of 2026, from October 1, 2026, to December 31, 2026. This decision was approved by the Board through a resolution by circulation, following his initial appointment for the third quarter of 2026. Mr. Malla is an Independent Director of the company.

Motilal Oswal ELSS Tax Saver Fund and other schemes of Motilal Oswal Mutual Fund have disclosed a disposal of 39,99,781 shares in Religare Enterprises Ltd, representing 1.1722% of the total share capital. This transaction, executed via market transactions on August 31, 2026, reduces their aggregate holding to 75,52,362 shares, or 2.2133% of the company's total voting capital. The total share capital of Religare Enterprises remains unchanged at 34,12,33,742 shares.